Braden G. Higgs
Adelaide, SA, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Efficacy of Medical Interventions for Erectile Dysfunction after Prostate Cancer Treatment: A Systematic Review and Network Meta-Analysis.
Journal: The world journal of men's health
Published: February 19, 2026
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.
Journal: The Lancet. Oncology
Published: February 06, 2026
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.
Journal: The Lancet. Oncology
Published: December 20, 2025
From Clinical Trials to Clinical Practice-Patterns of Practice Survey on Prostate SABR in Australia and New Zealand.
Journal: Advances in radiation oncology
Published: December 19, 2025
Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study.
Journal: BJU international
Published: August 22, 2025
Efficacy of SABR in Uncommon Subtypes of Primary Kidney Cancer: An Analysis From the International Radiosurgery Oncology Consortium of the Kidney.
Journal: International journal of radiation oncology, biology, physics
Published: May 12, 2025
SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II Trial.
Journal: International journal of radiation oncology, biology, physics
Published: December 10, 2024
Comparing post-treatment urinary and colorectal procedures in prostate cancer patients using population-based linked data.
Journal: International urology and nephrology
Published: October 24, 2024
Dose-Effect Relationship of Kidney Function After SABR for Primary Renal Cell Carcinoma: TROG 15.03 FASTRACK II.
Journal: International journal of radiation oncology, biology, physics
Published: January 11, 2024
Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection.
Journal: Clinical genitourinary cancer
Published: December 08, 2023
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Journal: The Lancet. Oncology
Published: November 14, 2023
Last Updated: 09/26/2026